Bioinformatics analysis to identify the relationship between human papillomavirus-associated cervical cancer, toll-like receptors and exomes: A genetic epidemiology study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Uterine Cervical Neoplasms*/genetics ; Uterine Cervical Neoplasms*/virology ; Toll-Like Receptors*/genetics ; Papillomavirus Infections*/genetics ; Papillomavirus Infections*/virology ; Computational Biology*/methods; Humans ; Female ; Adult ; Papillomaviridae/genetics ; Middle Aged ; Human Papillomavirus Viruses
    • Abstract:
      Introduction: Genetic variants may influence Toll-like receptor (TLR) signaling in the immune response to human papillomavirus (HPV) infection and lead to cervical cancer. In this study, we investigated the pattern of TLR expression in the transcriptome of HPV-positive and HPV-negative cervical cancer samples and looked for variants potentially related to TLR gene alterations in exomes from different populations.
      Materials and Methods: A cervical tissue sample from 28 women, which was obtained from the Gene Expression Omnibus database, was used to examine TLR gene expression. Subsequently, the transcripts related to the TLRs that showed significant gene expression were queried in the Genome Aggregation Database to search for variants in more than 5,728 exomes from different ethnicities.
      Results: Cancer and HPV were found to be associated (p<0.0001). TLR1(p = 0.001), TLR3(p = 0.004), TLR4(221060_s_at)(p = 0.001), TLR7(p = 0.001;p = 0.047), TLR8(p = 0.002) and TLR10(p = 0.008) were negatively regulated, while TLR4(1552798_at)(p<0.0001) and TLR6(p = 0.019) were positively regulated in HPV-positive patients (p<0.05). The clinical significance of the variants was statistically significant for TLR1, TLR3, TLR6 and TLR8 in association with ethnicity. Genetic variants in different TLRs have been found in various ethnic populations. Variants of the TLR gene were of the following types: TLR1(5_prime_UTR), TLR4(start_lost), TLR8(synonymous;missense) and TLR10(3_prime_UTR). The "missense" variant was found to have a risk of its clinical significance being pathogenic in South Asian populations (OR = 56,820[95%CI:40,206,80,299]).
      Conclusion: The results of this study suggest that the variants found in the transcriptomes of different populations may lead to impairment of the functional aspect of TLRs that show significant gene expression in cervical cancer samples caused by HPV.
      Competing Interests: The authors have declared that no competing interests exist.
      (Copyright: © 2024 Gomes et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Endocrinology. 2014 Apr;155(4):1453-65. (PMID: 24437488)
      Cold Spring Harb Perspect Biol. 2019 Oct 1;11(10):. (PMID: 30181377)
      Mol Med Rep. 2020 Feb;21(2):786-794. (PMID: 31789409)
      Mol Oncol. 2022 Feb;16(4):833-845. (PMID: 33830625)
      Tumori. 2017 Jan 21;103(1):81-86. (PMID: 28009429)
      Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:2-13. (PMID: 28964706)
      Front Immunol. 2023 Apr 25;14:1147950. (PMID: 37180114)
      Science. 2005 Aug 26;309(5739):1380-4. (PMID: 16123302)
      Cells. 2019 Jun 21;8(6):. (PMID: 31234354)
      Cien Saude Colet. 2019 Sep 09;24(9):3431-3442. (PMID: 31508761)
      Bull Cancer. 2014 Oct;101(10):E31-5. (PMID: 25373689)
      Int J Mol Sci. 2021 May 21;22(11):. (PMID: 34063805)
      J Educ Eval Health Prof. 2021;18:17. (PMID: 34325496)
      Gynecol Oncol. 2015 Aug;138(2):358-62. (PMID: 26024767)
      Mol Biol Rep. 2011 Oct;38(7):4715-21. (PMID: 21132533)
      Genome Med. 2023 Dec 25;15(1):107. (PMID: 38143269)
      Immunobiology. 2022 Mar;227(2):152187. (PMID: 35158151)
      Clin Dev Immunol. 2012;2012:785825. (PMID: 22013487)
      CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
      Genet Med. 2021 Jan;23(1):59-68. (PMID: 32884132)
      J Cancer. 2019 Jun 2;10(13):2969-2981. (PMID: 31281474)
      Cancer Res. 2007 May 15;67(10):4605-19. (PMID: 17510386)
      Gynecol Oncol. 2014 Nov;135(2):359-63. (PMID: 25135000)
      Genome Med. 2023 Jul 13;15(1):51. (PMID: 37443081)
      J Immunol. 2007 Mar 1;178(5):3186-97. (PMID: 17312167)
      Immunol Rev. 2018 Jan;281(1):233-247. (PMID: 29247989)
      Signal Transduct Target Ther. 2017 Nov 03;2:17055. (PMID: 29263932)
      BMC Med Genomics. 2020 Mar 9;13(1):35. (PMID: 32151264)
      G3 (Bethesda). 2022 Jan 4;12(1):. (PMID: 34791179)
      Genet Med. 2015 May;17(5):405-24. (PMID: 25741868)
      Biomed Res Int. 2021 Sep 12;2021:1157023. (PMID: 34552981)
      Int J Cancer. 2011 Feb 15;128(4):879-86. (PMID: 20473890)
      Handb Exp Pharmacol. 2022;276:161-174. (PMID: 34595581)
      Wiley Interdiscip Rev RNA. 2018 Jul;9(4):e1474. (PMID: 29582564)
      J Obstet Gynaecol. 2020 Jul;40(5):602-608. (PMID: 31500479)
      Biomark Med. 2023 Feb;17(3):133-142. (PMID: 37097031)
      Comput Biol Med. 2022 Sep;148:105903. (PMID: 35932731)
      Int J Mol Sci. 2023 Feb 03;24(3):. (PMID: 36769304)
      Biomark Res. 2022 Dec 7;10(1):89. (PMID: 36476317)
      Nat Commun. 2023 May 12;14(1):2744. (PMID: 37173324)
      PLoS One. 2015 Jul 30;10(7):e0133184. (PMID: 26226228)
      J Membr Biol. 2014 Jul;247(7):591-9. (PMID: 24878539)
      J Immunol Res. 2021 May 22;2021:9912188. (PMID: 34124272)
      Microb Pathog. 2021 Oct;159:105149. (PMID: 34416273)
      Sci Rep. 2019 Jul 5;9(1):9729. (PMID: 31278284)
      Chin J Cancer. 2011 May;30(5):344-50. (PMID: 21527067)
      Oncogene. 2008 Jan 7;27(2):190-9. (PMID: 18176600)
      Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4478-84. (PMID: 25288745)
      Lancet Infect Dis. 2005 Mar;5(3):156-64. (PMID: 15766650)
      Biol Sex Differ. 2023 Sep 18;14(1):60. (PMID: 37723501)
      Int J Med Sci. 2014 Apr 16;11(6):608-13. (PMID: 24782650)
      Biomed Res Int. 2017;2017:7830262. (PMID: 28626766)
      Infect Agent Cancer. 2020 Feb 17;15:12. (PMID: 32095158)
      Pathogens. 2022 Nov 16;11(11):. (PMID: 36422611)
      Mod Pathol. 2021 Jan;34(1):207-221. (PMID: 32699256)
      Gene. 2014 Oct 15;550(1):27-32. (PMID: 25106857)
    • Accession Number:
      0 (Toll-Like Receptors)
    • Publication Date:
      Date Created: 20240829 Date Completed: 20240829 Latest Revision: 20240903
    • Publication Date:
      20240903
    • Accession Number:
      PMC11361573
    • Accession Number:
      10.1371/journal.pone.0305760
    • Accession Number:
      39208235